ASCO GU 2026 Bladder Cancer

Viewing 1-20 of 70 articles

ASCO GU 2026: Induction Ipilimumab + Nivolumab Followed by Consolidating Chemoradiotherapy as Bladder-Sparing Treatment in Stage II/III Urothelial Carcinoma of the Bladder: The Phase 2 Indi-Blade Trial

ASCO GU 2026: Discussant: RETAIN trials and IMvigor011 trial

ASCO GU 2026: Discussant: The Era of ADCs for Urothelial Carcinoma Continues

ASCO GU 2026: Association of Non-Luminal Subtype with Overall Survival in High Risk NMIBC Patients: Biomarker Results from the Bladder Cancer Prognosis Programme

ASCO GU 2026: Circulating Tumor DNA Analysis from the Prospective pT0 Study of Systematic Endoscopic Evaluation in Patients Undergoing Radical Cystectomy for Bladder Cancer

ASCO GU 2026: ctDNA Monitoring of FGFR3-Altered Metastatic Urothelial Carcinoma Treated with Dabogratinib (TYRA-300) in the SURF301 Trial

ASCO GU 2026: Detecting FGFR3 Genomic Alterations in Liquid Biopsies from Patients with Clinically Advanced Urothelial Bladder Cancer

ASCO GU 2026: Drug-Releasing Intravesical Floating Technology (DRIFT) for Administration of Sequential Gemcitabine and Docetaxel in NMIBC

ASCO GU 2026: Integrating Genomic Profiling and Circulating Tumor DNA Monitoring to Optimize Surveillance Strategies in MIBC

ASCO GU 2026: Effect of Censorship in the Interpretation of Outcomes of Enfortumab Vedotin + Pembrolizumab in the EV-302 Phase 3 Randomized Clinical Trial

ASCO GU 2026: Interim Safety and Tolerability of TARA-002 in Patients with BCG-Naïve and Unresponsive High-Grade NMIBC in ADVANCED-2

ASCO GU 2026: Perioperative Enfortumab Vedotin + Pembrolizumab Versus Neoadjuvant Pembrolizumab in Cisplatin-Ineligible Patients with MIBC: An IPD-Based Comparative Analysis of KEYNOTE-905/EV-303 and PURE-01

ASCO GU 2026: Phase 1/2 Study of an Anti-PD-L1/IL-15 Variant Fusion Protein (SIM0237) in BCG-Unresponsive High-Risk NMIBC

ASCO GU 2026: Neoadjuvant Gemcitabine Intravesical System + Cetrelimab or Cetrelimab Alone in Patients with MIBC Ineligible For/refusing Neoadjuvant Cisplatin-Based Chemotherapy: Updated Perioperative Outcomes from SunRISe-4

ASCO GU 2026: Outcomes in Participants with BCG-Unresponsive HR-NMIBC Who Underwent Radical Cystectomy After Pembrolizumab: KEYNOTE-057 Cohort a Post Hoc Analysis

ASCO GU 2026: ADVANCED-2: Interim Efficacy and Safety Data in BCG-Unresponsive Participants with High-Grade NMIBC

ASCO GU 2026: Implementation of Patient Reported Outcomes as NMIBC Clinical Trial Endpoints

ASCO GU 2026: SASN-SPARING: A Phase 2 Trial of Sasanlimab Maintenance as Bladder-Sparing Option After Neoadjuvant Chemotherapy in Patients with MIBC

ASCO GU 2026: A Phase III Randomized Control Clinical Trial of Radiotherapy with Radiosensitization Versus Intravesical BCG Therapy for High-Risk NMIBC: TRAIN

ASCO GU 2026: EV-PRIME: Phase Ib/II Study of Enfortumab Vedotin and Pembrolizumab Combined with Radiotherapy as a Bladder-Sparing Trimodality Therapy in MIBC

1
2
3
4